Literature DB >> 12666655

IGF-I and NT-3 signaling pathways in developing oligodendrocytes: differential regulation and activation of receptors and the downstream effector Akt.

Jennifer K Ness1, Nina E Mitchell, Teresa L Wood.   

Abstract

A previous study from our laboratory demonstrated differences in the ability of insulin-like growth factor-I (IGF-I) and neurotrophin-3 (NT-3) to promote survival of pro-oligodendroblasts (pro-OLs) against glutamate-mediated apoptosis. In the current study, we tested whether submaximal concentrations of NT-3 would maintain receptor tyrosine kinase TrkC activation and Akt phosphorylation and thus promote long-term survival of the pro-OL against glutamate. Our results demonstrate that NT-3 at any concentration sufficient to activate the TrkC receptor results in a transient phosphorylation of the receptor and of Akt due, in part, to downregulation of the Trk receptor. In contrast, even submaximal IGF-I concentrations maintain long-term Akt activation and prevent glutamate-mediated apoptosis in pro-OLs. In addition, we also present data showing that IGF-I and NT-3 differentially activate their receptors and Akt depending on the maturational stage of the oligodendrocyte.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12666655     DOI: 10.1159/000069050

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  21 in total

Review 1.  Directing traffic in neural cells: determinants of receptor tyrosine kinase localization and cellular responses.

Authors:  Robert J Romanelli; Teresa L Wood
Journal:  J Neurochem       Date:  2008-06-01       Impact factor: 5.372

Review 2.  Glial development: the crossroads of regeneration and repair in the CNS.

Authors:  Vittorio Gallo; Benjamin Deneen
Journal:  Neuron       Date:  2014-07-16       Impact factor: 17.173

3.  Neurotrophin-3 is a novel angiogenic factor capable of therapeutic neovascularization in a mouse model of limb ischemia.

Authors:  Brunella Cristofaro; Oliver A Stone; Andrea Caporali; David Dawbarn; Nicholas Ieronimakis; Morayma Reyes; Paolo Madeddu; David O Bates; Costanza Emanueli
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-04-01       Impact factor: 8.311

Review 4.  Pharmacological approaches to intervention in hypomyelinating and demyelinating white matter pathology.

Authors:  Li-Jin Chew; Cynthia A DeBoy
Journal:  Neuropharmacology       Date:  2015-06-24       Impact factor: 5.250

Review 5.  Signals to promote myelin formation and repair.

Authors:  Carla Taveggia; Maria Laura Feltri; Lawrence Wrabetz
Journal:  Nat Rev Neurol       Date:  2010-04-20       Impact factor: 42.937

6.  R-Ras1 and R-Ras2 Are Essential for Oligodendrocyte Differentiation and Survival for Correct Myelination in the Central Nervous System.

Authors:  Miriam Sanz-Rodriguez; Agnès Gruart; Juan Escudero-Ramirez; Fernando de Castro; José María Delgado-García; Francisco Wandosell; Beatriz Cubelos
Journal:  J Neurosci       Date:  2018-05-02       Impact factor: 6.167

7.  Insulin-like growth factor-I (IGF-I) inhibits neuronal apoptosis in the developing cerebral cortex in vivo.

Authors:  Rebecca D Hodge; A Joseph D'Ercole; John R O'Kusky
Journal:  Int J Dev Neurosci       Date:  2007-03-24       Impact factor: 2.457

8.  Insulin-like growth factor-I-stimulated Akt phosphorylation and oligodendrocyte progenitor cell survival require cholesterol-enriched membranes.

Authors:  Robert J Romanelli; Kedar R Mahajan; Clifton G Fulmer; Teresa L Wood
Journal:  J Neurosci Res       Date:  2009-11-15       Impact factor: 4.164

9.  Neurotrophin-3 targets the translational initiation machinery in oligodendrocytes.

Authors:  Rochelle P Coelho; Larra M Yuelling; Babette Fuss; Carmen Sato-Bigbee
Journal:  Glia       Date:  2009-12       Impact factor: 7.452

10.  Constitutively active Akt induces enhanced myelination in the CNS.

Authors:  Ana I Flores; S Priyadarshini Narayanan; Emily N Morse; H Elizabeth Shick; Xinghua Yin; Grahame Kidd; Robin L Avila; Daniel A Kirschner; Wendy B Macklin
Journal:  J Neurosci       Date:  2008-07-09       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.